<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    Year
    2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

    254 Results

    Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights

    March 6, 2023

    Biodesix announces its financial and operating results for the fourth quarter and year ended December 31, 2022 (fiscal 2022) and provided a corporate update.

    Biodesix to Participate at Cowen’s 43rd Annual Healthcare Conference

    March 1, 2023

    Scott Hutton, Chief Executive Officer of Biodesix, will participate in a fireside chat and host in-person investor meetings at Cowen’s 43rd Annual Healthcare Conference.

    Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

    February 21, 2023

    Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update.

    Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test

    December 19, 2022

    announced positive coverage decisions from four private payers including Blue Cross Blue Shield of North Carolina, Blue Cross Blue Shield of South Carolina, Blue Cross Blue Shield of Kansas City, and Capital District Physician’s Health Plan (CDPHP) of New York

    Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors

    December 16, 2022

    Biodesix announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company’s Board of Directors effective January 3, 2023.

    Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine

    December 12, 2022

    Biodesix named the leading Proteomics Solutions Company in the U.S. by Life Sciences Review Magazine issue, Top 10 Proteomics Solutions Companies of 2022.

    Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock

    November 17, 2022

    Biodesix announced the pricing of an underwritten public offering of 30,500,000 shares of its common stock at a price to the public of $1.15 per share, before underwriting discounts and commissions.

    Biodesix Announces Proposed Public Offering of Common Stock

    November 16, 2022

    Biodesix announced that it has commenced an underwritten public offering of $30 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses.

    Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million

    November 16, 2022

    Biodesix announced that it has obtained a term loan facility for up to $50 million from Perceptive Advisors, a leading healthcare investment firm focused on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare.

    Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

    November 10, 2022

    Data confirms the ability of the VeriStrat® test to predict outcomes in patients with Non-small Cell Lung Cancer treated with immunotherapy regimens.
    1 2 3 4 5 6 7 8 9